Pulmonary Drug Delivery Market in United Kingdom

Pulmonary Drug Delivery in United Kingdom Trends and Forecast

The future of the pulmonary drug delivery market in United Kingdom looks promising with opportunities in the hospitals & clinic and home care markets. The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2031 with a CAGR of 2.5% from 2025 to 2031. The pulmonary drug delivery market in United Kingdom is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising prevalence of respiratory diseases, growing awareness of the benefits of pulmonary drug delivery, and the increasing demand for home-based healthcare services.

• Lucintel forecasts that, within the application category, chronic obstructive pulmonary disease (COPD) segment will remain the largest segment over the forecast period due to the increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

• Within the end use category, hospitals & clinics will remain the larger segment due to the growing number of hospital pharmacies across the globe.

Emerging Trends in the Pulmonary Drug Delivery Market in United Kingdom

The pulmonary drug delivery market in the United Kingdom is evolving rapidly, driven by technological advancements, increasing respiratory disease prevalence, and the need for better management solutions. Innovations in inhalation devices, biologics, and digital health technologies are revolutionizing patient care, making treatments more personalized and effective. As asthma, COPD, and other respiratory conditions remain widespread, the UK market is focusing on improving patient outcomes through more accessible and efficient pulmonary drug delivery options. Below are five key emerging trends reshaping this market in the United Kingdom.

• Advancements in Smart Inhalers and Connected Devices: Smart inhalers are gaining traction in the UK, combining advanced sensors with inhalers to track medication usage and inhalation technique. These devices connect to mobile apps, allowing patients to monitor their adherence while also providing healthcare providers with real-time data for better disease management. The integration of connected devices is improving personalized care, reducing hospitalizations, and ensuring more accurate medication delivery, ultimately helping patients better manage asthma and COPD with improved outcomes.

• Growth of Biologics and Targeted Respiratory Therapies: The rise of biologic therapies, particularly monoclonal antibodies, is revolutionizing the treatment of severe asthma and COPD in the UK. These biologic drugs target the underlying inflammation causing symptoms, offering patients with uncontrolled conditions an effective alternative to traditional inhalers. Biologics are especially beneficial for patients who do not respond well to standard treatments. This trend is improving the quality of life for patients with severe respiratory diseases and reducing the burden on healthcare systems.

• Integration of Telemedicine in Pulmonary Disease Management: Telemedicine has seen rapid adoption in the UK for managing chronic respiratory conditions. Patients can now consult with healthcare professionals remotely, eliminating the need for in-person visits and improving access to care, particularly for those in rural areas. Telemedicine services also include virtual follow-ups, symptom monitoring, and medication adjustments. This trend is streamlining care, ensuring patients remain engaged in their treatment plans, and ultimately improving adherence to medication regimens while reducing healthcare costs.

• Emphasis on Patient-Centric Pulmonary Care: There is an increasing shift towards patient-centric care in the UK, where treatments are tailored to individual needs. This trend focuses on enhancing patient involvement in decision-making, improving their understanding of disease management, and providing them with more control over their health. Patient education, digital tools, and personalized treatment regimens are empowering patients to manage their conditions more effectively. This shift is expected to improve patient satisfaction and long-term health outcomes by ensuring therapies align with each patient’s specific needs.

• Focus on Sustainable and Eco-Friendly Inhalers: Sustainability is becoming a growing concern in the UK’s pulmonary drug delivery market, with a push towards eco-friendly inhalers. Many inhalers use propellants that contribute to global warming, but new eco-friendly devices are being developed with lower environmental impact. These inhalers use environmentally friendly propellants and recyclable materials, responding to increasing consumer demand for greener products. As sustainability becomes more important in the healthcare sector, these innovations are expected to reduce the environmental footprint while maintaining the same level of treatment efficacy. The emerging trends in the UK’s pulmonary drug delivery market—smart inhalers, biologics, telemedicine integration, patient-centric care, and eco-friendly inhalers—are transforming the landscape of respiratory disease management. These innovations are enhancing treatment efficacy, improving patient engagement, and ensuring greater accessibility to care. As the UK continues to embrace these trends, the pulmonary drug delivery market will see improved outcomes for patients with chronic respiratory diseases, while also addressing environmental concerns and advancing healthcare efficiency.

Recent Developments in the Pulmonary Drug Delivery Market in United Kingdom

The pulmonary drug delivery market in the United Kingdom is undergoing a period of rapid transformation, driven by technological innovations, regulatory support, and a rising prevalence of respiratory diseases. The market is shifting towards more advanced, patient-centered solutions, emphasizing ease of use, improved efficacy, and sustainability. Below are five key recent developments that are shaping the market in the UK.

• Approval of Smart Inhalers by UK Regulatory Bodies: The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved several smart inhalers equipped with sensors to monitor usage. These devices provide real-time feedback to patients and healthcare providers, helping improve medication adherence. Smart inhalers can alert patients if they miss a dose or use the inhaler incorrectly. This approval marks a significant step in improving patient outcomes for chronic respiratory diseases such as asthma and COPD, enabling more effective management through personalized care.

• Introduction of New Inhaler Devices with Enhanced Drug Delivery: New inhaler devices with improved drug delivery systems have been introduced in the UK. These devices, such as soft mist inhalers and dry powder inhalers, offer more efficient medication delivery to the lungs, reducing waste and improving patient compliance. This development ensures that patients receive their prescribed doses more effectively, leading to better disease control and fewer exacerbations of chronic respiratory conditions. Enhanced delivery systems also allow for more accurate dosing, contributing to improved overall treatment outcomes.

• Expansion of NHS Pulmonary Disease Initiatives: The National Health Service (NHS) in the UK has expanded its pulmonary disease initiatives, including better access to inhalers and respiratory medications. These programs aim to provide early intervention for patients with asthma, COPD, and other chronic respiratory diseases. By offering free or subsidized medications and encouraging adherence through patient education, the NHS is improving the management of respiratory diseases and reducing the burden of hospital admissions due to uncontrolled conditions. These initiatives ensure more equitable access to effective pulmonary care across the country.

• Increased Focus on Biologic Therapies for Severe Respiratory Diseases: The UK has seen a significant increase in the use of biologic therapies to treat severe asthma and COPD. These therapies target specific inflammatory pathways, offering more effective and targeted treatment options for patients with severe, uncontrolled diseases. Biologic drugs, such as monoclonal antibodies, have shown to reduce flare-ups, improve lung function, and enhance overall patient quality of life. The increased use of biologics in the UK is helping to reduce healthcare system strain by improving disease control for severe cases.

• Introduction of Environmentally Friendly Inhalers: There is an increasing focus on sustainability within the UK pulmonary drug delivery market. Many companies are now introducing inhalers that use propellants with a lower global warming potential. These environmentally friendly inhalers are designed to reduce the carbon footprint of respiratory treatments while maintaining the same effectiveness. With growing environmental concerns, the shift toward sustainable inhalers is not only beneficial for the planet but also aligns with consumer preferences for greener healthcare solutions. Recent developments such as the approval of smart inhalers, the introduction of advanced inhaler devices, NHS initiatives, increased biologic therapy adoption, and the launch of eco-friendly inhalers are significantly impacting the UK’s pulmonary drug delivery market. These innovations are improving treatment adherence, patient outcomes, and overall disease management, while also addressing sustainability concerns. As the UK continues to prioritize patient-centered care and environmental responsibility, the market will likely see continued growth, driving better care and more efficient pulmonary disease management.

Strategic Growth Opportunities for Pulmonary Drug Delivery Market in United Kingdom

The United Kingdom’s pulmonary drug delivery market is witnessing significant advancements due to rising awareness of respiratory diseases, the increasing prevalence of conditions like asthma and COPD, and technological innovations in drug delivery devices. With a well-established healthcare system and increased research into respiratory therapies, the market offers substantial growth potential. These developments present opportunities to enhance patient outcomes, reduce healthcare costs, and improve disease management. Below are key growth opportunities in the pulmonary drug delivery market across different applications in the United Kingdom.

• Smart Inhalers for Enhanced Monitoring and Compliance: Smart inhalers, which offer real-time feedback on medication usage, are poised to transform respiratory disease management in the United Kingdom. These devices track patient adherence and provide data to both patients and healthcare professionals, improving the accuracy of treatment plans. As chronic respiratory diseases become more prevalent, the demand for smart inhalers will increase. By offering more personalized care, smart inhalers not only enhance patient outcomes but also reduce healthcare costs associated with non-adherence, making them a critical growth opportunity in the market.

• Portable Nebulizers for Home-Based Care: Portable nebulizers are becoming a popular option for patients seeking flexible home-based treatments for respiratory conditions. The UK healthcare system is increasingly focusing on providing care at home to alleviate the pressure on hospitals. Portable nebulizers allow patients with chronic respiratory diseases to administer treatments at their convenience, enhancing patient independence and reducing the need for frequent hospital visits. This shift towards home care is expected to drive the growth of portable nebulizers in the United Kingdom, as they become an essential component of respiratory care at home.

• Biologic Therapies for Advanced Disease Management: Biologic therapies, such as monoclonal antibodies, represent a significant growth opportunity in the pulmonary drug delivery market in the United Kingdom. These therapies provide targeted treatments for severe asthma and other chronic conditions that do not respond well to conventional medications. As the UK population ages and the incidence of severe respiratory diseases rises, the demand for biologic therapies will continue to grow. Biologic drugs, in combination with advanced drug delivery systems, offer more effective and personalized treatment options, thereby expanding market potential.

• Combination Therapy Inhalers for Simplified Regimens: Combination therapy inhalers, which deliver multiple medications in one device, are expected to see increasing adoption in the United Kingdom. These inhalers offer patients a more simplified and efficient way to manage respiratory conditions such as asthma and COPD. By combining bronchodilators and corticosteroids, these devices improve adherence, reduce medication complexity, and enhance overall disease management. As the number of patients with chronic respiratory conditions increases, the demand for combination inhalers will continue to grow, driving the market forward.

• Government Support for Respiratory Health Programs: The United Kingdom government’s support for public health initiatives and respiratory health programs is driving the adoption of pulmonary drug delivery systems. Initiatives aimed at improving awareness of respiratory diseases and increasing access to treatments are essential for market growth. Public funding for new treatments, especially for severe asthma and COPD, combined with healthcare policies supporting patient access to advanced devices, will continue to support market expansion. Government interventions play a vital role in enhancing market dynamics and ensuring equitable access to pulmonary drug delivery systems. The strategic growth opportunities in the pulmonary drug delivery market in the United Kingdom, including smart inhalers, portable nebulizers, biologic therapies, combination inhalers, and government support, are fostering market expansion. As healthcare reforms continue to focus on home care and disease management, these innovations will enhance patient care and improve disease outcomes. With a growing demand for advanced treatments and delivery systems, the UK market is set to experience sustained growth in the coming years.

Pulmonary Drug Delivery Market in United Kingdom Driver and Challenges

The pulmonary drug delivery market in the United Kingdom is influenced by a mix of technological, economic, and regulatory factors. Increasing rates of chronic respiratory diseases, advances in drug delivery technologies, and governmental support for healthcare are primary drivers of market growth. However, challenges such as high treatment costs, regulatory hurdles, and patient non-adherence to medication remain critical obstacles. Addressing these factors is key to unlocking the market’s full potential and ensuring the availability of effective treatments for respiratory patients in the UK. The factors responsible for driving the pulmonary drug delivery market in United Kingdom include:

• Technological Advancements in Drug Delivery Devices: The rapid development of innovative drug delivery devices, such as smart inhalers and advanced nebulizers, is a major driver of the pulmonary drug delivery market in the United Kingdom. These devices improve patient adherence, enhance disease management, and allow for more personalized care. Technological advancements are helping address key challenges in respiratory care, such as medication errors and inconsistent treatment. With increased adoption of these advanced devices, the UK market will continue to expand, improving outcomes for patients with chronic respiratory diseases.

• Growing Prevalence of Respiratory Diseases: The increasing prevalence of asthma, COPD, and other respiratory conditions in the United Kingdom is driving the demand for advanced pulmonary drug delivery systems. An aging population and environmental factors, such as air pollution, are contributing to the rise in these diseases. As a result, there is a growing need for more effective and convenient treatments for respiratory patients. The higher demand for treatment options will propel market growth, leading to increased adoption of inhalers, nebulizers, and biologic therapies.

• Government Support and Healthcare Initiatives: Government funding and healthcare initiatives aimed at improving respiratory health are a significant driver in the UK pulmonary drug delivery market. Public health campaigns that increase awareness of respiratory diseases and promote access to advanced therapies are essential for market growth. Policies that support the reimbursement and affordability of modern drug delivery systems are also helping drive market expansion. Government support plays a pivotal role in ensuring that innovative treatments reach the wider patient population, thus expanding market opportunities.

• Increased Focus on Personalized Medicine: The shift towards personalized medicine in the United Kingdom is driving demand for targeted therapies and advanced drug delivery devices. Biologic therapies, which offer personalized treatments for conditions like severe asthma, are gaining popularity. By tailoring treatments to the specific needs of patients, personalized medicine enhances the effectiveness of pulmonary drug delivery systems. As the demand for biologic drugs and individualized care continues to rise, the market will see increased growth in biologic delivery devices and related technologies.

• Private Sector Investments in Pulmonary Health: Private sector investment in respiratory health and drug delivery technologies is helping fuel growth in the UK market. Companies are investing heavily in research and development to create more effective and patient-friendly drug delivery devices. These investments are also encouraging innovation and competition, which benefits patients by providing access to a wider range of treatment options. With increasing private sector contributions, the pulmonary drug delivery market will continue to evolve, offering improved therapies and treatment outcomes for patients. Challenges in the pulmonary drug delivery market in United Kingdom are:

• High Cost of Advanced Treatments: The high cost of biologic therapies and advanced drug delivery devices is a key challenge in the United Kingdom. Although these treatments offer significant benefits, their high price can limit accessibility for some patients, particularly those without adequate insurance coverage. These cost barriers may restrict market growth and patient access to the latest therapies. Addressing these cost challenges, through government subsidies or insurance reforms, will be essential to ensure broader access to advanced pulmonary drug delivery systems.

• Regulatory Barriers and Approval Delays: Regulatory hurdles and lengthy approval processes for new drugs and devices pose a significant challenge to the pulmonary drug delivery market in the United Kingdom. Delays in the approval of innovative therapies and delivery systems can limit patient access to the latest treatments. To overcome this challenge, regulatory bodies must streamline approval processes and work closely with manufacturers to ensure timely access to new therapies. Addressing regulatory delays is crucial for maintaining the momentum of market growth in the UK.

• Patient Non-Adherence to Medication: Non-adherence to prescribed treatment regimens remains a critical challenge in the United Kingdom’s pulmonary drug delivery market. Even with advanced devices, many patients fail to follow their medication schedules properly, leading to suboptimal disease management. Factors such as forgetfulness, difficulty using devices correctly, and lack of motivation contribute to non-adherence. Addressing this challenge through patient education, improved device design, and better monitoring systems will be essential for ensuring the success of pulmonary drug delivery treatments. Technological innovations, increasing disease prevalence, government support, and growing focus on personalized medicine are driving the growth of the pulmonary drug delivery market in the United Kingdom. However, challenges such as high treatment costs, regulatory hurdles, and patient non-adherence remain significant obstacles. By addressing these issues, the market has the potential to grow further, offering more effective treatments and improving patient outcomes across the United Kingdom. The United States pulmonary drug delivery market is experiencing significant growth, driven by technological innovations, rising awareness of respiratory diseases, and an increasing demand for efficient, targeted treatments. As the prevalence of conditions like asthma and COPD rises, there is a growing focus on improving medication adherence, treatment efficacy, and patient outcomes. The market is shifting toward more advanced, personalized drug delivery solutions that ensure better management of chronic respiratory diseases. Below are five emerging trends shaping the pulmonary drug delivery landscape in the United States.

• Expansion of Dry Powder Inhalers (DPIs) Usage: Dry Powder Inhalers (DPIs) are becoming increasingly popular in the U.S. due to their ease of use and the precise drug delivery they provide. DPIs do not require propellants, making them more environmentally friendly. These inhalers are easier to use for patients and require less coordination, making them an ideal choice for many individuals, including elderly patients. The growth of DPIs enhances the efficiency of drug delivery, reduces waste, and ensures better medication adherence among patients with asthma and COPD.

• Growth of Personalized Pulmonary Medicine: Personalized medicine is gaining traction in the U.S. pulmonary drug delivery market, where therapies are tailored to the genetic and molecular profiles of individual patients. This trend focuses on optimizing treatment effectiveness by identifying specific disease mechanisms. Personalized inhalers, for example, are designed to target the unique needs of patients based on their condition, ensuring better treatment outcomes. By customizing therapies for each patient, the approach aims to minimize side effects, improve efficacy, and enhance overall patient satisfaction.

• Increased Focus on Targeted Drug Delivery Systems: Targeted drug delivery systems, which allow medications to be delivered directly to the lungs, are seeing increasing adoption in the United States. These systems are designed to enhance the local effect of drugs while minimizing systemic side effects. By improving the precision of drug delivery, these systems are helping to better manage chronic diseases like asthma and COPD. Targeted therapies ensure that medications reach the lungs directly where they are needed most, improving treatment efficacy and reducing unnecessary side effects.

• Development of Biologic Therapies for Severe Respiratory Diseases: Biologic therapies, which focus on targeting specific molecular pathways involved in respiratory diseases, are seeing significant growth in the U.S. market. Monoclonal antibodies, for instance, offer a new approach to treating severe asthma and COPD by directly addressing the underlying inflammatory processes. These therapies provide significant benefits to patients who do not respond to traditional inhalers. The development of biologic treatments is expected to improve the management of severe respiratory conditions, providing better outcomes and reducing hospitalizations.

• Rise of Digital Health Integration in Pulmonary Care: Digital health solutions, including mobile apps and connected inhalers, are transforming the pulmonary drug delivery landscape in the U.S. By enabling real-time tracking of medication adherence, symptom monitoring, and health data analysis, these tools are enhancing patient engagement and improving disease management. Digital integration ensures better communication between patients and healthcare providers, helping to identify potential issues early and adjust treatments accordingly. The rise of digital health in pulmonary care is leading to improved treatment adherence and overall patient satisfaction. Emerging trends such as the increased use of dry powder inhalers, personalized medicine, targeted drug delivery systems, biologic therapies, and digital health integration are reshaping the pulmonary drug delivery market in the United States. These trends are enhancing treatment precision, improving patient adherence, and providing new options for patients with chronic respiratory conditions. As the market continues to evolve, these innovations promise to improve the overall management of respiratory diseases, leading to better outcomes and more personalized care for patients. Recent Developments in the pulmonary drug delivery market in United States; The United States pulmonary drug delivery market has been undergoing rapid development, characterized by the introduction of advanced therapies, new inhaler devices, and digital health solutions. These developments are aimed at improving patient care, enhancing treatment efficiency, and addressing the rising burden of respiratory diseases. Below are five key recent developments that are influencing the pulmonary drug delivery market in the United States.

• Approval of Next-Generation Inhalers by FDA; The U.S. Food and Drug Administration (FDA) has recently approved several next-generation inhalers, including devices with more efficient drug delivery systems. These inhalers offer improved medication adherence, more accurate dosing, and enhanced patient convenience. The new devices, which include both dry powder inhalers and metered-dose inhalers, allow for better control over drug delivery, helping patients with asthma and COPD manage their conditions more effectively. The FDA’s approval of these devices represents a major step in improving respiratory disease management.

• Introduction of Targeted Inhalation Therapies; Targeted inhalation therapies, designed to deliver medication directly to the lungs, have been introduced in the U.S. These therapies are especially beneficial for patients with severe asthma and COPD, as they ensure that medications reach the lungs more efficiently while minimizing side effects. The use of these targeted therapies is expected to improve the quality of life for patients by providing faster relief, reducing inflammation, and offering more personalized treatment options. This development marks a significant advancement in managing chronic respiratory diseases.

• Expansion of Biologic Drug Offerings for Asthma and COPD; Biologic drugs for the treatment of severe asthma and COPD are expanding in the U.S. These treatments, such as monoclonal antibodies, target specific pathways in the immune system, addressing the underlying causes of inflammation in the lungs. The expansion of biologic drug offerings is providing more options for patients who have not responded to traditional therapies, offering better control over symptoms and fewer flare-ups. The growth of biologics is helping reduce hospital visits and improving the overall management of severe respiratory diseases.

• Increased Investment in Pulmonary Disease Research; The U.S. government and private sector have significantly increased their investments in pulmonary disease research, focusing on innovative drug delivery technologies and new treatment options. This funding is driving advancements in personalized medicine, biologics, and smart inhalers. Research into improving drug formulations and inhaler devices is helping develop more efficient treatments for asthma, COPD, and other respiratory conditions. Increased investment in research is expected to accelerate the development of new, more effective therapies, enhancing patient outcomes and reducing the long-term burden of respiratory diseases.

• Growth of Telemedicine and Remote Monitoring for Respiratory Care; Telemedicine and remote patient monitoring have been rapidly adopted in the U.S. to manage chronic respiratory diseases. With the integration of digital tools, patients can receive consultations remotely, track their symptoms, and share data with healthcare providers. This approach enhances access to care, especially in underserved regions, and ensures better disease management. The growth of telemedicine is reducing the need for in-person visits, improving convenience for patients, and allowing for more continuous monitoring and timely intervention, ultimately leading to better management of chronic respiratory diseases. Conclusion; Recent developments in the U.S. pulmonary drug delivery market, including the approval of next-generation inhalers, the introduction of targeted therapies, the expansion of biologic drugs, increased research investments, and the growth of telemedicine, are transforming the management of respiratory diseases. These innovations are improving the precision of treatment delivery, enhancing patient engagement, and offering more personalized and effective solutions. The continued progress in pulmonary drug delivery technologies promises to improve outcomes for patients with chronic respiratory conditions, reduce healthcare costs, and drive further innovation in the field.

List of Pulmonary Drug Delivery Market in United Kingdom Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, pulmonary drug delivery companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pulmonary drug delivery companies profiled in this report include:

• Company 1

• Company 2

• Company 3

• Company 4

• Company 5

Pulmonary Drug Delivery Market in United Kingdom by Segment

The study includes a forecast for the pulmonary drug delivery market in United Kingdom by application, end use, and distribution channel.

Pulmonary Drug Delivery Market in United Kingdom by Application [Analysis by Value from 2019 to 2031]:

• Asthma

• Chronic Obstructive Pulmonary Disease

• Allergic Rhinitis

• Cystic Fibrosis

• Others

Pulmonary Drug Delivery Market in United Kingdom by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics

• Home Care

Pulmonary Drug Delivery Market in United Kingdom by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacies

• Retail Pharmacies

• E-Commerce

Features of the Pulmonary Drug Delivery Market in United Kingdom

Market Size Estimates: Pulmonary drug delivery in United Kingdom market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends and forecasts by various segments. Segmentation Analysis: Pulmonary drug delivery in United Kingdom market size by application, end use, and distribution channel in terms of value ($B). Growth Opportunities: Analysis of growth opportunities in different application, end use, and distribution channel for the pulmonary drug delivery in United Kingdom. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pulmonary drug delivery in United Kingdom. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What are the major drivers influencing the growth of the pulmonary drug delivery market in United Kingdom? Answer: The major drivers for this market are the rising prevalence of respiratory diseases, growing awareness of the benefits of pulmonary drug delivery, and the increasing demand for home-based healthcare services. Q2. What are the major segments for pulmonary drug delivery market in United Kingdom? Answer: The future of the pulmonary drug delivery market in United Kingdom looks promising with opportunities in the hospitals & clinic and home care markets. Q3. Which pulmonary drug delivery market segment in United Kingdom will be the largest in future? Answer: Lucintel forecasts that chronic obstructive pulmonary disease (COPD) segment will remain the largest segment over the forecast period due to the increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease. Q4. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.